F-star Therapeutics to Participate in Upcoming Investor Conferences
07 1월 2022 - 10:00PM
F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage
biopharmaceutical company dedicated to developing next-generation
bispecific immunotherapies to transform the lives of patients with
cancer, today announced that it will participate in the H.C.
Wainwright Bioconnect Conference and the B. Riley Securities’ 2022
Oncology Conference taking place virtually on January 10-13, and
January 27-28, 2022, respectively.
During the conferences, Eliot Forster, CEO of F-star
Therapeutics, Inc. will discuss the Company's corporate strategy,
bispecific antibody discovery platform and highlight the company’s
four clinical-stage programs.
Details of the upcoming conferences are shown below:
H.C. Wainwright Bioconnect Conference (January 10-13,
2022)Format: Fireside chat and one-on-one meetingsDate:
January 10, 2022Time: 8:00 am EST
A replay will be available on the F-star website for 90 days
following the conference.
B. Riley Securities’ Oncology Conference (January 27-28,
2022)Format: Fireside chat and one-on-one meetingsDate:
January 27, 2022Time: 8:00 am EST
About F-star Therapeutics, Inc.
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical
company dedicated to developing next generation immunotherapies to
transform the lives of patients with cancer. F-star is pioneering
the use of tetravalent (2+2) bispecific antibodies to create a
paradigm shift in cancer therapy. The Company has four
second-generation immuno-oncology therapeutics in the clinic, each
directed against some of the most promising IO targets in drug
development, including LAG-3 and CD137. F-star’s proprietary
antibody discovery platform is protected by an extensive
intellectual property estate. F-star has over 500 granted patents
and pending patent applications relating to its platform technology
and product pipeline. The Company has attracted multiple
partnerships with biopharma targeting significant unmet needs
across several disease areas, including oncology, immunology, and
CNS.
For more information visit our website and follow us
on LinkedIn and Twitter.
For further information, please contact:
For investor inquiries
Lindsey TrickettVP Investor Relations &
Communications+1 240 543 7970lindsey.trickett@f-star.com
For media inquiries
Helen ShikShik Communications LLC +1
617-510-4373 helen@shikcommunications.com
F star Therapeutics (NASDAQ:FSTX)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
F star Therapeutics (NASDAQ:FSTX)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024